Contents
Current Cancer Drug Targets, Volume 13 - Number 3
Diverse Mechanisms of AKT Pathway Activation in Human Malignancy
, 13(3): 234 - 244Mitchell Cheung and Joseph R. Testa
DOI: 10.2174/1568009611313030002
Oxygen-independent Regulation of HIF-1: Novel Involvement of PI3K/ AKT/mTOR Pathway in Cancer
, 13(3): 245 - 251Faton Agani and Bing-Hua Jiang
DOI: 10.2174/1568009611313030003
Roles of EGFR, PI3K, AKT, and mTOR in Heavy Metal-Induced Cancer
, 13(3): 252 - 266Richard L. Carpenter and Bing-Hua Jiang
DOI: 10.2174/1568009611313030004
Targeting the mTOR Pathway in Tumor Malignancy
, 13(3): 267 - 277Hengmiao Cheng, Marlena Walls, Sangita M. Baxi and Min-Jean Yin
DOI: 10.2174/1568009611313030005
IDO+ DCs and Signalling Pathways
, 13(3): 278 - 288Yue Wang, Bao-Hong Yang, Hui Li, Shui Cao, Xiu-Bao Ren and Jin-Pu Yu
DOI: 10.2174/15680096113139990073
Novel HSP90 Inhibitor NVP-AUY922 Enhances the Anti-tumor Effect of Temsirolimus Against Oral Squamous Cell Carcinoma
, 13(3): 289 - 299Tatsuo Okui, Tsuyoshi Shimo, Takuya Fukazawa, Nur Mohammad Monsur Hassan, Tatsuki Honami, Soichiro Ibaragi, Munenori Takaoka, Yoshio Naomoto and Akira Sasaki
DOI: 10.2174/1568009611313030007
Targeting Tyrosine Kinase Receptors in Hepatocellular Carcinoma
, 13(3): 300 - 312Jordi Muntane, Angel J. De la Rosa, Fernando Docobo, Rocio Garcia-Carbonero and Francisco J. Padillo
DOI: 10.2174/15680096113139990075
Novel Agents, Combinations and Sequences for the Treatment of Advanced Renal Cell Carcinoma: When is the Revolution Coming?
, 13(3): 313 - 325Matteo Santoni, Mimma Rizzo, Luciano Burattini, Rossana Berardi, Giacomo Carteni and Stefano Cascinu
DOI: 10.2174/1568009611313030009
P-glycoprotein Inhibition as a Therapeutic Approach for Overcoming Multidrug Resistance in Cancer: Current Status and Future Perspectives
, 13(3): 326 - 346Ziyad Binkhathlan and Afsaneh Lavasanifar
DOI: 10.2174/15680096113139990076
Webmaster Contact: info@benthamscience.org